Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis [0.03%]
艾乐替尼治疗ALK阳性的转移性非小细胞肺癌患者的系统评价和网络 meta 分析
Daniel Samacá-Samacá,Laura Prieto-Pinto,Andrés Yepes Peréz et al.
Daniel Samacá-Samacá et al.
Aim: To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced ALK-positive NSCLC. ...
Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary [0.03%]
晚期肺鳞癌患者治疗考虑因素：简易版
Edgardo S Santos,Estelamari Rodriguez
Edgardo S Santos
What is this article about?: This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung. ...
Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy [0.03%]
与所有经支气管活组织检查标本相比含有肿瘤的活组织检查标本的比例
Shinnosuke Takemoto,Mutsumi Ozasa,Remi Mizuta et al.
Shinnosuke Takemoto et al.
Background: The lung cancer biopsy specimens obtained by endobronchial ultrasound-guide sheath (EBUS-GS) trans lung biopsy occasionally do not contain cancer cells. It is a problem that there is a possibility that they ma...
Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience [0.03%]
NSCLC辅助化疗的预后和毒副作用：一项单中心研究体验
Christopher Cronin,Shahid Iqbal,Abdul R Farooq et al.
Christopher Cronin et al.
Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population. ...
Coral Olazagasti,Nagashree Seetharamu,Nina Kohn et al.
Coral Olazagasti et al.
Aim: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The US Preventive Services Task Force and National Comprehensive Cancer Network recommend annual low-dose computed tomography (LDCT) for eligi...
Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC [0.03%]
艾法尼替延缓EGFR-G719A突变非小细胞肺癌进展的效果较好
Amit A Kulkarni,Naomi Fujioka,Lucia Reinhardt et al.
Amit A Kulkarni et al.
We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initia...
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study [0.03%]
西班牙新诊断转移性非小细胞肺癌的PD-L1检测和临床管理：MOREL研究
Belen Rubio-Viqueira,Margarita Majem Tarruella,Martín Lázaro et al.
Belen Rubio-Viqueira et al.
Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. ...
Enabling patients in effective self-management of breathlessness in lung cancer: the neglected pillar of personalized medicine [0.03%]
肺癌患者有效自我管理呼吸困难：被忽视的精准医疗重要支柱
Doris Howell
Doris Howell
Globally, engagement of patients in the self management of disease and symptom problems has become a health policy priority to improve health outcomes in cancer. Unfortunately, little attention has been focused on the provision of self-mana...
Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data [0.03%]
免疫检查点抑制剂治疗自身免疫或炎症性疾病相关实体瘤患者的回顾性分析
Virginia Calvo,Marta Andrés Fernández,Ana Collazo-Lorduy et al.
Virginia Calvo et al.
Aim: Immune checkpoint inhibitors (ICIs) are a cornerstone in cancer treatment but they can induce immune-related adverse events (irAEs). Furthermore, patients with pre-existing autoimmune and/or inflammatory disease (AID...
Disparities in lung cancer screening rates among the Hispanic/LatinX population [0.03%]
拉美裔人群中肺癌筛查率的差异性
Coral Olazagasti,Nagashree Seetharamu
Coral Olazagasti